Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.
Status: Enrolling
Updated:  3/1/2016
Eastern Regional Medical Center
mi
from
Philadelphia, PA
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.
Status: Enrolling
Updated: 3/1/2016
Eastern Regional Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.
Status: Enrolling
Updated:  3/1/2016
University of California at San Francisco
mi
from
San Francisco, CA
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.
Status: Enrolling
Updated: 3/1/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.
Status: Enrolling
Updated:  3/1/2016
Washington University, St. Louis
mi
from
St. Louis, MO
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.
Status: Enrolling
Updated: 3/1/2016
Washington University, St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection
Status: Enrolling
Updated:  3/1/2016
St. Louis Children's Hospital
mi
from
St. Louis, MO
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection
Status: Enrolling
Updated: 3/1/2016
St. Louis Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection
Status: Enrolling
Updated:  3/1/2016
North Shore‐LIJ Health System Laboratories
mi
from
Lake Success, NY
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection
Status: Enrolling
Updated: 3/1/2016
North Shore‐LIJ Health System Laboratories
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection
Status: Enrolling
Updated:  3/1/2016
Scott & White Memorial Hospital
mi
from
Temple, TX
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection
Status: Enrolling
Updated: 3/1/2016
Scott & White Memorial Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection
Status: Enrolling
Updated:  3/1/2016
St. Joseph's Hospital
mi
from
Hamilton,
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection
Status: Enrolling
Updated: 3/1/2016
St. Joseph's Hospital
mi
from
Hamilton,
Click here to add this to my saved trials
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Bardstown, KY
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Bardstown, KY
Click here to add this to my saved trials
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Woburn, MA
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Woburn, MA
Click here to add this to my saved trials
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Niles, MI
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Niles, MI
Click here to add this to my saved trials
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Layton, UT
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Layton, UT
Click here to add this to my saved trials
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
A Pilot, Double-blind, Placebo-controlled, Randomized Clinical Trial of mRNA-transfected Autologous Dendritic Cells in Subjects With Well-controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy
Status: Enrolling
Updated:  3/3/2016
Infectious Disease Unit; Massachusetts General Hospital
mi
from
Boston, MA
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
A Pilot, Double-blind, Placebo-controlled, Randomized Clinical Trial of mRNA-transfected Autologous Dendritic Cells in Subjects With Well-controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy
Status: Enrolling
Updated: 3/3/2016
Infectious Disease Unit; Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Tolerant Kidney Transplant Recipients
Identification and Mechanistic Investigations of Tolerant Transplant Recipients
Status: Enrolling
Updated:  3/3/2016
Emory University
mi
from
Atlanta, GA
Study of Tolerant Kidney Transplant Recipients
Identification and Mechanistic Investigations of Tolerant Transplant Recipients
Status: Enrolling
Updated: 3/3/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Tolerant Kidney Transplant Recipients
Identification and Mechanistic Investigations of Tolerant Transplant Recipients
Status: Enrolling
Updated:  3/3/2016
University of Wisconsin
mi
from
Madison, WI
Study of Tolerant Kidney Transplant Recipients
Identification and Mechanistic Investigations of Tolerant Transplant Recipients
Status: Enrolling
Updated: 3/3/2016
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Tolerant Kidney Transplant Recipients
Identification and Mechanistic Investigations of Tolerant Transplant Recipients
Status: Enrolling
Updated:  3/3/2016
NIH Clinical Center
mi
from
Bethesda, MD
Study of Tolerant Kidney Transplant Recipients
Identification and Mechanistic Investigations of Tolerant Transplant Recipients
Status: Enrolling
Updated: 3/3/2016
NIH Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Tolerant Kidney Transplant Recipients
Identification and Mechanistic Investigations of Tolerant Transplant Recipients
Status: Enrolling
Updated:  3/3/2016
Swedish Medical Center
mi
from
Seattle, WA
Study of Tolerant Kidney Transplant Recipients
Identification and Mechanistic Investigations of Tolerant Transplant Recipients
Status: Enrolling
Updated: 3/3/2016
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection
Status: Enrolling
Updated:  3/3/2016
University of California at San Francisco
mi
from
San Francisco, CA
Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection
Status: Enrolling
Updated: 3/3/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen
Status: Enrolling
Updated:  3/4/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen
Status: Enrolling
Updated: 3/4/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigator Site
mi
from
Bellevue, NE
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigator Site
mi
from
Bellevue, NE
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Melbourne, FL
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Melbourne, FL
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Binghamton, NY
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Binghamton, NY
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Jonesboro, AR
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigational Site
mi
from
Charleston, SC
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Cleveland, OH
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Dayton, OH
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
324, Novartis Investigational Site
mi
from
Niles, MI
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
324, Novartis Investigational Site
mi
from
Niles, MI
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Hialeah, FL
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Hialeah, FL
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Miami, FL
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
313, Novartis Investigational Site
mi
from
Augusta, KA
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
313, Novartis Investigational Site
mi
from
Augusta, KA
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Saint Paul, MN
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Omaha, NE
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Raleigh, NC
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
337, Novartis Investigational Site
mi
from
Mt Pleasant, SC
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
337, Novartis Investigational Site
mi
from
Mt Pleasant, SC
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
Novartis Investigative Site
mi
from
Spokane, WA
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated:  3/5/2016
101, Novartis Investigational Site
mi
from
Espoo,
Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents
Status: Enrolling
Updated: 3/5/2016
101, Novartis Investigational Site
mi
from
Espoo,
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Dothan, AL
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Bakersfield, CA
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Englewood, CO
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Bradenton, FL
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Lauderdale Lakes, FL
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Maitland, FL
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Miami, FL
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Orlando, FL
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Wellington, FL
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Wellington, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Atlanta, GA
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Columbus, GA
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated:  3/7/2016
Clinical Research Facility
mi
from
Marietta, GA
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Status: Enrolling
Updated: 3/7/2016
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials